Juvenile Diabetes News and Research

Latest Juvenile Diabetes News and Research

Tolerx publishes follow-up data from study of otelixizumab therapy for new onset T1DM patients

Tolerx, Inc., today announced the publication in Diabetologia, the journal of the European Association for the Study of Diabetes, of the four-year follow-up clinical data from new onset type 1 diabetes (T1DM) patients (age 12-39) who received a single short course of therapy with otelixizumab (ChAglyCD3).

16 Mar 2010

XOMA initiates Phase 2 clinical trial of XOMA 052 in Type 1 diabetes patients

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced the initiation of a Phase 2 clinical trial of XOMA 052, its antibody to interleukin-1 beta (IL-1 beta), in Type 1 diabetes patients. Funding for the trial is being provided by the Juvenile Diabetes Research Foundation International, the largest patient advocacy organization of Type 1 diabetes research worldwide.

12 Mar 2010

Valley Presbyterian Hospital announces opening of premier Amputation Prevention Center

Valley Presbyterian Hospital is proud to announce the planned red-carpet grand-opening on March 17th of its premier Amputation Prevention Center (APC), an integrated limb-preservation center that is one of the nation’s only facilities of its kind.

4 Mar 2010

Osiris Therapeutics' net income for fourth-quarter 2009 increases to $15.7M

Osiris Therapeutics, Inc., the leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, cardiovascular and orthopedic areas, announced today its results for the fourth quarter and year ended December 31, 2009.

24 Feb 2010

Diabetic retinopathy: 5.3M U.S adults suffer

Despite major progress in diagnosis and treatment, diabetic retinopathy remains the major cause of blindness in adults under 60 in the U.S., said Thomas C. Lee, director, Retina Institute in The Vision Center at Childrens Hospital Los Angeles, associate professor of clinical ophthalmology at the Keck School of Medicine of the University of Southern California and attending physician at Doheny Eye Institute.

12 Feb 2010

Artificial pancreas can help manage diabetes in kids overnight

In a landmark study in children and teenagers with type 1 diabetes, JDRF-funded researchers at the University of Cambridge showed that using a first-generation artificial pancreas system overnight can lower the risk of low blood sugar emergencies while sleeping, and at the same time improve diabetes control.

6 Feb 2010

EVMS researchers identify source that causes Type 1 diabetes

Doctors at Eastern Virginia Medical School's Strelitz Diabetes Center have been stalking the culprit responsible for Type 1 diabetes. Now, they are one step closer.

5 Feb 2010

Type 1 diabetes: Regeneration exhibits potential as a possible cure

A hormone responsible for the body's stress response is also linked to the growth of insulin-producing cells in the pancreas, according to JDRF- funded researchers at the Salk Institute for Biological Studies in California. The findings are the latest advances to underscore the potential for regeneration as a key component of a possible cure for type 1 diabetes.

4 Feb 2010

Osiris Therapeutics completes enrollment in Prochymal MSC therapy Phase II trial for type 1 diabetes

Osiris Therapeutics, Inc. today announced that it has achieved a $750,000 milestone payment from the Juvenile Diabetes Research Foundation (JDRF) for completing enrollment in a Phase II clinical trial evaluating Prochymal, an adult mesenchymal stem cell (MSC) therapy, as a treatment for patients recently diagnosed with type 1 diabetes. The milestone is the fourth in a series of payments resulting from JDRF’s partnership with Osiris for the development of a therapy for type 1 diabetes.

27 Jan 2010

Findings may point toward potential therapies for type 2 diabetes

In people who put on a lot of weight, or whose bodies start developing the inability to use insulin effectively that leads toward type 2 diabetes, the pancreas typically ramps up its supply of insulin-generating "beta" cells, at least partly by replication of the existing cells.

27 Jan 2010

Findings may provide new insights into diabetes; suggest novel targets for drug intervention

The neuropeptide corticotropin-releasing factor (CRF) makes cameo appearances throughout the body, but its leading role is as the opening act in the stress response, jump-starting the process along the hypothalamus-pituitary-adrenal (HPA) axis. Researchers at the Salk Institute for Biological Studies have found that CRF also plays a part in the pancreas, where it increases insulin secretion and promotes the division of the insulin-producing beta cells.

22 Jan 2010

Fast Forward, JDRF announce collaborative partnership with Axxam SpA

Fast Forward, LLC, the commercial drug development arm of the National Multiple Sclerosis Society, and the Juvenile Diabetes Research Foundation (JDRF), the leader in research leading to a cure for type 1 diabetes in the world today announced a collaborative partnership with Axxam SpA -- a leading company in conducting early-stage discovery research programs for the life science industry -- to develop new treatments for two autoimmune diseases, multiple sclerosis (MS) and type 1 diabetes (T1D).

20 Jan 2010

JDRF and BD join to develop novel insulin delivery products for treatment of type 1 diabetes

The Juvenile Diabetes Research Foundation (JDRF) and BD (Becton, Dickinson and Company) announced today an innovative program aimed at improving the treatment of type 1 diabetes by developing novel insulin delivery products to enhance the use of insulin pumps.

From BD (Becton, Dickinson and Company) 20 Jan 2010

CBAI collaborates with Center for Stem Cell Awareness to re-sell its stem cell collection and storage services

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com) focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, announced today that it has contracted with The Center for Stem Cell Awareness to re-sell its stem cell collection and storage services.

19 Jan 2010

Evidence suggests insulin pumps may help in maintaining blood glucose levels in type 1 diabetic patients

A new evidence review suggests that using a pump to deliver insulin continuously — instead of taking three or more daily injections — might result in better control of blood sugar for people with type 1 diabetes.

18 Jan 2010

Researchers discover potential treatment for blinding disease

The discovery of an inflammatory mediator key to the blinding effects of diabetic retinopathy is pointing toward a potential new treatment, Medical College of Georgia researchers said.

18 Jan 2010

JDRF and Animas partner to develop an automated system for better control of type 1 diabetes

The Juvenile Diabetes Research Foundation today announced an innovative partnership with Animas Corporation to develop an automated system to help people with type 1 diabetes better control their disease -- the first step on the path to what would be among the most revolutionary advancements in treating type 1 diabetes: the development of an artificial pancreas, a fully automated system to dispense insulin to patients based on real-time changes in blood sugar levels.

18 Jan 2010

Sangamo BioSciences initiates two new clinical trials of ZFP Therapeutics

Sangamo BioSciences, Inc. announced the initiation of two new clinical trials of ZFP Therapeutics, a Phase 2b study in diabetic neuropathy (DN) and a Phase 1 trial in glioblastoma, as well as the renewal of $3.0 million in funding for the Phase 2b trial by the Juvenile Diabetes Research Foundation International (JDRF).

11 Jan 2010

Scientists and clinicians address diagnosis and treatment for autoimmune and autoinflammatory diseases

Autoimmune and autoinflammatory diseases are a major health issue. The National Institutes of Health reports that up to 23.5 million Americans are afflicted. The American Autoimmune Related Diseases Association reports the number is closer to 50 million. Scientists and clinicians at The University of Texas Health Science Center at Houston can address the diagnosis and treatment of these conditions, as well as the latest advances in research.

8 Jan 2010

Patient enrollment in Tolerx's Phase 3 clinical study DEFEND-1 completed

Tolerx, Inc., today announced the completion of patient enrollment in its Phase 3 clinical study DEFEND-1, which is evaluating the safety and efficacy of otelixizumab, a targeted T cell immunomodulator, in patients with new-onset autoimmune type 1 diabetes.

8 Jan 2010

Juvenile Diabetes News and Research

Latest Juvenile Diabetes News and Research

Tolerx publishes follow-up data from study of otelixizumab therapy for new onset T1DM patients

XOMA initiates Phase 2 clinical trial of XOMA 052 in Type 1 diabetes patients

Valley Presbyterian Hospital announces opening of premier Amputation Prevention Center

Osiris Therapeutics' net income for fourth-quarter 2009 increases to $15.7M

Diabetic retinopathy: 5.3M U.S adults suffer

Artificial pancreas can help manage diabetes in kids overnight

EVMS researchers identify source that causes Type 1 diabetes

Type 1 diabetes: Regeneration exhibits potential as a possible cure

Osiris Therapeutics completes enrollment in Prochymal MSC therapy Phase II trial for type 1 diabetes

Findings may point toward potential therapies for type 2 diabetes

Findings may provide new insights into diabetes; suggest novel targets for drug intervention

Fast Forward, JDRF announce collaborative partnership with Axxam SpA

JDRF and BD join to develop novel insulin delivery products for treatment of type 1 diabetes

CBAI collaborates with Center for Stem Cell Awareness to re-sell its stem cell collection and storage services

Evidence suggests insulin pumps may help in maintaining blood glucose levels in type 1 diabetic patients

Researchers discover potential treatment for blinding disease

JDRF and Animas partner to develop an automated system for better control of type 1 diabetes

Sangamo BioSciences initiates two new clinical trials of ZFP Therapeutics

Scientists and clinicians address diagnosis and treatment for autoimmune and autoinflammatory diseases

Patient enrollment in Tolerx's Phase 3 clinical study DEFEND-1 completed

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Juvenile Diabetes News and Research

Latest Juvenile Diabetes News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in